Tag Archives: venture capital

Make Your Mark at RESI JPM with the New Company Presentation Track 

12 Nov

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Showcase your brand, services, and expertise to a global life science audience 

Life Science Nation (LSN) is introducing a new opportunity at RESI JPM 2026, the Company Presentation Track, designed for service providers, established companies, and later-stage ventures seeking to elevate their brand visibility and connect with decision-makers across the global life science ecosystem. 

Taking place January 12-13, 2026, at the Marriott Marquis in San Francisco, RESI JPM will also feature three days of virtual partnering on January 14, 19–20. RESI JPM will bring together hundreds of early-stage life science and healthcare companies and over 500 global investors for two full days of partnering, investor panels, and networking. 

The new Company Presentation Track offers organizations a unique platform to deliver a 15-minute presentation highlighting their business, market positioning, and value proposition. Unlike the Innovator’s Pitch Challenge, which focuses on fundraising and investor feedback for early-stage startups, these company presentations are designed for firms looking to expand their visibility, attract new clients, and strengthen their strategic partnerships. 

Participants in this track will have the opportunity to: 

  • Present their company, products, and services to an engaged global audience. 
  • Build brand recognition among investors, partners, and industry peers. 
  • Demonstrate thought leadership and industry expertise in a highly visible format. 

This new feature adds to RESI’s robust mix of investor panels, workshops, partnering meetings, and exhibition opportunities, making it a comprehensive platform for business development and partnership-building across the life science sector. 

Make your mark at RESI JPM. Share your story, elevate your brand, and connect with investors, innovators, and service providers driving the future of healthcare innovation. 

To apply, select Company Presentation during your RESI JPM registration or contact the RESI team at RESI@lifesciencenation.com for more information. 

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , ,

LSN Fundraising Bootcamp at London Bio-Innovation Week 2025 

12 Nov

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Refine your fundraising strategy and investor engagement with hands-on insights from industry experts.

Life Science Nation (LSN) invites early-stage life science and healthcare executives to an exclusive Fundraising Bootcamp during London Bio-Innovation Week 2026. This free, half-day workshop is designed to help entrepreneurs strengthen their fundraising strategy, improve investor engagement, and sharpen their pitching skills through interactive, expert-led sessions.

Date and Time: Tuesday, December 2, 1:00 PM – 5:00 PM
Location: Fieldfisher Law Firm, Riverbank House, 2 Swan Lane, London
Cost: Free

The LSN Fundraising Bootcamp brings together investors, fundraising professionals, and industry experts to provide a clear view of the current investor landscape and actionable strategies for early-stage companies preparing for their next raise.

Session topics include It All Starts with The Story, Global Partnering Campaign – Investor Landscape, GTL & GPC, LSN Event Partnering Process, and Maximizing The Power Of Your Pitch. The program concludes with a live Sharktank-style session where participants pitch their companies to a panel of experts and receive real-time feedback.

This interactive event offers practical guidance and the chance to connect with key players in the global life science ecosystem.

To register, please complete the contact form:

Sign Up Fundraising Bootcamp Register for RESI London

Tags: , , , , ,

RESI JPM 2026: A Global Hub for Life Science Connections 

4 Nov

By Matt Stanton, VP Sales US West, Central and South America, LSN

The Redefining Every Stage of Investment (RESI) Conference returns to San Francisco for RESI JPM 2026, taking place January 12–13 at the San Francisco Marriott Marquis. This two-day in-person event will be followed by three days of online partnering on January 14, 19, and 20, providing multiple opportunities to connect with investors, strategic partners, and early-stage innovators across biotech, medtech, diagnostics, and digital health.

RESI JPM is one of the the biggest and well attended investor partnering events held concurrently alongside JP Morgan Healthcare Week , RESI JPM serves as an high-impact venue for early-stage companies to meet investors and strategic partners in a focused, partnering-driven environment. Previous RESI JPM conferences have drawn more than a thousand participants, including over 700 early-stage life science investors, innovators, and industry leaders.

This year, RESI JPM 2026 welcomes companies and delegations representing more than 36 countries, reflecting the truly global reach of the RESI community. The event brings together entrepreneurs and investors from every major life science hub, creating a dynamic platform for cross-border collaboration and innovation.

We’re honored to host international cohorts from: 

  • Brisbane Economic Development Agency (BEDA) – Government Organization, Australia
  • Kobe Biomedical Innovation Cluster (KBIC) – Incubator/Accelerator, Japan
  • Monash University – Tech Hub, Australia
  • Ontario (Canada)
  • Enterprise Singapore
  • Ganesha Lab – Latin America
  • Apex Brasil
  • One Nucleus (UK)
  • O2h (UK)

These groups join a growing network of innovators supported by Life Science Nation’s (LSN) global ecosystem. LSN and the RESI Conference Series have built connections spanning every continent, linking life science startups with investors ranging from seed-stage venture funds to corporate pharma and strategic partners. The international participation seen at RESI JPM underscores LSN’s mission to connect early-stage technologies with capital and expertise across borders.

We are also grateful for the ongoing collaboration of our global partners, including Freemind, Biocat, BioPartner UK, Life Science British Columbia, Arizona Bio, Biotech Gate, MaRS Discovery District, MassChallenge, and Eurasanté — and many more.

Join us in San Francisco and online for RESI JPM 2026 to engage with the global life science community and accelerate your innovation journey. There is still time to apply to pitch in the Innovator’s Pitch Challenge, where startups gain exposure to investors and industry experts providing valuable feedback and connections.

To date, 90 companies have reported raising $1.29 billion from connections that began at RESI — your next breakthrough could be just one conversation away.

Register for RESI JPM Appy to Pitch at RESI JPM

Tags: , , , ,

Beyond Borders: How to Prepare for Partnering Success at RESI London in the “Winter” 

4 Nov

By Greg Mannix, VP, EMEA Business Development, LSN

When was the last time you spoke directly with an investor? Or better yet how often do you have the chance to meet with multiple qualified investors in a single day? 

In today’s challenging investment climate, life science startups can’t afford to slow down their fundraising efforts. Capital is still out there, but it requires thinking beyond borders. 

To thrive in this “winter,” fundraising CEOs must: 

  • Step outside their regional ecosystems 
  • Build global visibility 
  • Connect directly with investors, in-licensors, and strategic partners who are still actively deploying capital 

That is exactly what RESI London 2025 is designed to help you do. 

Why Partnering Conferences Matter 

Partnering conferences, like RESI, give startups a fast, efficient way to meet investors who are aligned with their technology, stage, and strategy. Instead of spending months chasing introductions, companies can meet dozens of potential partners across two or three days. These concentrated interactions save time, reduce travel costs, and dramatically increase fundraising success rates. 

How to Prepare for a Partnering Conference 

Preparation determines success. Before meetings begin, make sure your company profile, pitch deck, and meeting strategy are ready. 

Join Life Science Nation’s free Partnering Tutorial Webinar on Monday, November 10 at 10 AM Eastern to learn how to navigate the RESI Partnering Platform, refine your outreach, and get ready to meet investors. 

Sign Up Free Webinar

RESI’s Unique Approach to Partnering 

Unlike most conferences, which offer only basic scheduling tools, the RESI Partnering Platform is built specifically for early-stage life sciences. It features a curated database of investor profiles gathered through direct interviews. Startups can filter investors by type, indication, and development stage to find their most relevant matches. This data-driven approach makes your meetings more targeted and impactful. 

RESI Survival Guide 

To help fundraising executives make the most of RESI, LSN developed the RESI Survival Guide, outlining five essential steps to partnering success. It covers how to identify the right investors, structure your day, and follow up effectively after the event. 

Ways to Partner: Standard vs. Premier Access 

Premier Access attendees enjoy additional benefits, including early access to investor profiles, enhanced visibility, and dedicated support from the LSN team. Whether you choose Standard or Premier, every investor profile on the RESI platform is verified and interviewed to ensure a high-quality partnering experience. 

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , ,

ApexBrasil and ABIQUIFI Deepen Strategic Alliance with Life Science Nation to Globalize Brazil’s Life Science Ecosystem and Leveraging the RESI JPM January Event 

28 Oct

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

São Paulo – Boston | October 2025

Brazil is taking a significant step toward global integration in the life sciences. Last week, ApexBrasil (the Brazilian Trade and Investment Promotion Agency) and ABIQUIFI (the Brazilian Association of Pharmaceutical Inputs Industry) hosted Life Science Nation (LSN) and Ganesha Labs in São Paulo for a week of meetings, workshops, and strategic dialogues with key stakeholders from across the national innovation and investment landscape. 

The visit culminated during the Corporate Venture in Brasil 2025 Conference, held in São Paulo and co-hosted by ApexBrasil, which gathered leading investors, corporate venture leaders, development agencies, and innovation stakeholders to strengthen Brazil’s position in the global market. 

At the conference, LSN’s CEO, Dennis Ford, delivered a masterclass on running global fundraising campaigns and building two-way innovation bridges between regional science and global capital. This was followed by a panel discussion, “Where Brazil Is and Where We Should Aim Towards,” featuring KX Ventures, IKJ, Sebrae, Ganesha Labs, and Life Science Nation, and moderated by Marcos Valadares of ABIQUIFI. 

Over several days surrounding the conference, ApexBrasil and ABIQUIFI facilitated a series of high-level introductions that connected LSN and Ganesha Labs with leaders from accelerators, investment groups, and research institutions across Brazil. These discussions focused on aligning Brazil’s growing innovation infrastructure with global commercialization frameworks and investor networks. 

The São Paulo visit capped two years of collaboration between the organizations, during which ApexBrasil and ABIQUIFI have sent multiple cohorts of Brazilian life-science companies to LSN’s Redefining Every Stage of Investment JPM events and LSN Labs training programs. 

Together, they have provided Brazilian entrepreneurs with a structured path to international investors and licensing partners, and a deeper understanding of how to prepare and execute a global fundraising campaign. 

This ongoing collaboration is laying the groundwork for Brazil to become a formal anchor node in the LSN Global Partnering Ecosystem. This worldwide network links regional innovation hubs to global capital and corporate partners. Through continued coordination, the parties aim to establish a lasting two-way innovation bridge between Brazil and LSN’s international ecosystem, enabling Brazilian technologies to access global markets while channeling international investors and strategic partners into the country’s rapidly expanding life-science sector. 

According to Dennis Ford, Founder and CEO of Life Science Nation, 

“Brazil’s scientific depth and entrepreneurial momentum make it one of the most exciting emerging markets in life sciences. ApexBrasil and ABIQUIFI are doing exactly what global investors want to see—creating a coordinated pathway that connects local innovation with international capital and commercialization opportunities. LSN is proud to help Brazil take this next step.” 

Norberto Prestes, CEO of ABIQUIFI, emphasized the export and funding side of the bridge: 

“Brazil has a rich foundation of science and talent. Our goal is to help these innovations secure the visibility, funding, and partnerships they need to reach international markets. The collaboration with LSN provides the structure and access needed to make that happen.” 

Debora Lima of ApexBrasil highlighted the importance of bringing international investors into the Brazilian ecosystem: 

“Our mission is to connect Brazil with the world—to bring investors, partners, and collaborators to see firsthand the innovation emerging here. Working with LSN allows us to open new channels for global capital to engage directly with Brazilian startups and research institutions.” 

About Life Science Nation

Life Science Nation (LSN) is a global matching and partnering engine that connects early-stage life-science companies with investors and licensing partners through its integrated ecosystem—including the LSN Investor & Licensing Partner Database, the RESI Conference Series, and LSN Labs Accelerator. LSN has supported more than 400 companies in raising over $5 billion in verified funding worldwide.

About ApexBrasil

ApexBrasil promotes Brazilian products and services abroad and attracts foreign investment to strategic sectors of the Brazilian economy, strengthening national competitiveness and international presence.

About ABIQUIFI

ABIQUIFI represents the Brazilian Pharmaceutical Inputs Industry, advancing innovation, quality, and competitiveness across the national health and life-sciences sector.

Registration now open:

  • RESI London 2025 (Dec. 4, 8&9) – [Register]
  • RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
  • RESI Europe 2026 (March 23-25) – [Register]

Tags: , , , , , , , , , , ,

RESI London 2025: An International Hub for Connections 

28 Oct

By Greg Mannix, VP, EMEA Business Development, LSN

The Redefining Every Stage of Investment (RESI) Conference is coming back to London on December 4th — and it’s shaping up to be bigger and better than ever. After a successful debut in 2024, RESI London returns to unite global investors, strategic partners, and early-stage innovators across biotech, medtech, diagnostics, and digital health. 

In today’s challenging funding landscape, breaking out of your regional bubble to build global relationships is essential. That’s exactly what RESI delivers — a trusted international platform where meaningful connections spark real partnerships and deals. 

With 54 conferences held across three continents since 2012, RESI has become a cornerstone of the global life science community, helping startups find the right investors, and investors find their next breakthrough. 

This December, RESI London will welcome international Tech Hubs and Regional Organizations collaborating through startup cohorts, promotional activities, and partner initiatives. 

We’re excited to welcome cohorts from:

  • Ontario (Canada)
  • CEIN Navarra (Spain) 
  • OneNucleus (UK) 

And we’re grateful for the ongoing collaboration of our global partners, including:
BioPartner UK, O2h (UK), Genopole, Lyonbiopole & Eurasanté (France), Life Science Zurich BP (Switzerland), BioM & BioRN (Germany), Biocat & Asebio (Spain), BioIndustry Park (Italy), PBio (Portugal), Business Regions Gotheborg/Skane (Sweden) — and many more. 

Join us in London on December 4th to connect with the global life science ecosystem and take your innovation to the next level. There is still time to pitch in the Innovator’s Pitch Challenge APPLY HERE 

90 companies have documented raising $1.29 B from connections started at RESI. Read More. 

Register for RESI London Appy to Pitch at RESI London

Tags: , , , ,

Kobe Biomedical Innovation Cluster (KBIC) Joins RESI JPM 2026 as Gold Sponsor

28 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is proud to announce that the Kobe Biomedical Innovation Cluster (KBIC) will serve as a sponsor for RESI JPM 2026, continuing its mission to promote innovation, entrepreneurship, and global collaboration in life sciences. 

As part of this sponsorship, KBIC will host the Kansai Life Sciences Accelerator Program (KLSAP) 2025 Demo Day at RESI JPM 2026 on Tuesday, January 13, 12:00 – 2:00pm PT at the Marriott Marquis San Francisco. The Demo Day will feature 3 startups that are part of the KLSAP 2025 Cohort as well as other member companies of KBIC, to be announced as the event approaches. This initiative will provide participating companies with global exposure, strategic investor connections, and the opportunity to pitch to an international audience of early-stage investors and strategic partners across life science and healthcare sectors.

Interested in joining and receiving updates on the KLSAP 2025 Demo Day? Please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.  

Introduction of Kobe Biomedical Innovation Cluster (KBIC)
Located in the heart of Kobe, Japan, the Kobe Biomedical Innovation Cluster is one of the nation’s leading ecosystems dedicated to the advancement of biomedical research and commercialization. With more than 340 organizations, including research institutes, hospitals, and life science companies, KBIC plays a vital role in bridging academia, government, and industry to accelerate innovation and improve global health outcomes. 

By partnering with RESI JPM 2026, KBIC aims to strengthen international collaboration and support Japanese startups seeking to expand their networks and raise global awareness for their technologies. Through this continued engagement, KBIC and LSN will work together help founders access global capital and strategic resources to advance from concept to commercialization. 

About Kansai Life Sciences Accelerator Program (KLSAP)
Powered by KBIC, the Kansai Life Sciences Accelerator Program (KLSAP) supports early-stage life science and healthcare startups in the Kansai region through tailored mentorship, commercialization guidance, and access to global investor networks. 

The 2025 KLSAP Cohort will participate in RESI JPM 2026 to present their innovations to a diverse investor audience, gain valuable feedback, and establish partnerships that can help drive their technologies toward global markets. The cohort’s participation exemplifies KBIC’s commitment to supporting international expansion and facilitating cross-border collaboration in life sciences. 3 companies have been selected for this year’s KLSAP Cohort, with descriptions of each company added below:

C-Biomex
Founded in 2017, C-Biomex is a bio-venture dedicated to advancing novel theranostics using its proprietary peptide discovery platform, CUS™. The platform enables identification of peptides with high stability and specificity through a three-step process involving a high-purity library, an innovative screening protocol that minimizes background interactions, and direct sequencing via a proprietary algorithm. C-Biomex focuses on radiopharmaceutical development, positioning itself at the intersection of diagnostics and therapeutics to accelerate peptide-based solutions for global biomedical applications.

GeneMedicine
GeneMedicine, founded in 2014 and based in Seoul, develops oncolytic viruses engineered to selectively replicate in and kill cancer cells while stimulating an anti-tumor immune response. Its GM-oAd platform is designed for systemic delivery of oncolytic adenoviruses with enhanced tumor specificity, immune activation, and ability to overcome physical tumor barriers. In addition to its therapeutic pipeline, GeneMedicine is expanding into CDMO services and novel drug-delivery systems, building a sustainable and diversified business model.

iXgene
iXgene is a Japanese life sciences company focused on developing therapies for intractable diseases using genome editing and induced pluripotent stem (iPS) cell technology. Its proprietary platform combines advanced genome editing tools, such as CRISPR, with iPS-derived therapeutics targeting indications including malignant brain tumors and brain injury. iXgene collaborates with academic institutions and pharmaceutical partners to translate next-generation regenerative and gene therapies into the clinic, aiming to address high-unmet-need central nervous system diseases. 

LSN and KBIC invites all investors, industry leaders, and innovators to meet the KLSAP 2025 Cohort at RESI JPM 2026. Together, they will continue to advance global innovation and foster meaningful connections across the life sciences ecosystem. 

Register for RESI JPM

Tags: , , , , , , , , , ,

← Older Entries
Newer Entries →